Back to Search Start Over

Within-Host Rhinovirus Evolution in Upper and Lower Respiratory Tract Highlights Capsid Variability and Mutation-Independent Compartmentalization.

Authors :
Makhsous N
Goya S
AvendaƱo CC
Rupp J
Kuypers J
Jerome KR
Boeckh M
Waghmare A
Greninger AL
Source :
The Journal of infectious diseases [J Infect Dis] 2024 Feb 14; Vol. 229 (2), pp. 403-412.
Publication Year :
2024

Abstract

Background: Rhinovirus (RV) infections can progress from the upper (URT) to lower (LRT) respiratory tract in immunocompromised individuals, causing high rates of fatal pneumonia. Little is known about how RV evolves within hosts during infection.<br />Methods: We sequenced RV complete genomes from 12 hematopoietic cell transplant patients with infection for up to 190 days from both URT (nasal wash, NW) and LRT (bronchoalveolar lavage, BAL). Metagenomic and amplicon next-generation sequencing were used to track the emergence and evolution of intrahost single nucleotide variants (iSNVs).<br />Results: Identical RV intrahost populations in matched NW and BAL specimens indicated no genetic adaptation is required for RV to progress from URT to LRT. Coding iSNVs were 2.3-fold more prevalent in capsid over nonstructural genes. iSNVs modeled were significantly more likely to be found in capsid surface residues, but were not preferentially located in known RV-neutralizing antibody epitopes. Newly emergent, genotype-matched iSNV haplotypes from immunocompromised individuals in 2008-2010 could be detected in Seattle-area community RV sequences in 2020-2021.<br />Conclusions: RV infections in immunocompromised hosts can progress from URT to LRT with no specific evolutionary requirement. Capsid proteins carry the highest variability and emergent mutations can be detected in other, including future, RV sequences.<br />Competing Interests: Potential conflicts of interest . A. L. G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic; and research support from Gilead and Merck, outside of the described work. A. W. reports research support from Pfizer, Amazon, GlaxoSmithKline/Vir, Ansun Biopharma, and Allovir; receiving personal fees from Kyorin Pharmaceutical and Vir Biotechnology; and receiving grants from Amazon and VB Tech, all outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.<br /> (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Details

Language :
English
ISSN :
1537-6613
Volume :
229
Issue :
2
Database :
MEDLINE
Journal :
The Journal of infectious diseases
Publication Type :
Academic Journal
Accession number :
37486790
Full Text :
https://doi.org/10.1093/infdis/jiad284